vs

Side-by-side financial comparison of Mind Medicine (MindMed) Inc. (DFTX) and XMax Inc. (XWIN). Click either name above to swap in a different company.

XMax Inc. is the larger business by last-quarter revenue ($1.8M vs $906.0K, roughly 2.0× Mind Medicine (MindMed) Inc.). On growth, XMax Inc. posted the faster year-over-year revenue change (-11.8% vs -16.1%).

Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.

XMax Inc. is a global tech firm focused on Web3 gaming infrastructure and interactive entertainment solutions. It builds custom game development toolkits, decentralized asset systems and cross-platform gaming products for developers and consumers in North America, APAC and Europe.

DFTX vs XWIN — Head-to-Head

Bigger by revenue
XWIN
XWIN
2.0× larger
XWIN
$1.8M
$906.0K
DFTX
Growing faster (revenue YoY)
XWIN
XWIN
+4.3% gap
XWIN
-11.8%
-16.1%
DFTX

Income Statement — Q4 FY2023 vs Q4 FY2025

Metric
DFTX
DFTX
XWIN
XWIN
Revenue
$906.0K
$1.8M
Net Profit
$-23.9M
Gross Margin
40.3%
Operating Margin
-2450.8%
-59.3%
Net Margin
-2634.0%
Revenue YoY
-16.1%
-11.8%
Net Profit YoY
-386.7%
EPS (diluted)
$-0.58
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DFTX
DFTX
XWIN
XWIN
Q4 25
$1.8M
Q3 25
$9.8M
Q2 25
$2.6M
Q1 25
$2.6M
Q4 24
$2.0M
Q3 24
$2.6M
Q2 24
$2.7M
Q1 24
$2.4M
Net Profit
DFTX
DFTX
XWIN
XWIN
Q4 25
Q3 25
$-1.1M
Q2 25
$-289.9K
Q1 25
$-338.9K
Q4 24
Q3 24
$-2.5M
Q2 24
$-563.5K
Q1 24
$-1.5M
Gross Margin
DFTX
DFTX
XWIN
XWIN
Q4 25
40.3%
Q3 25
10.1%
Q2 25
50.2%
Q1 25
45.7%
Q4 24
42.8%
Q3 24
45.1%
Q2 24
44.4%
Q1 24
42.8%
Operating Margin
DFTX
DFTX
XWIN
XWIN
Q4 25
-59.3%
Q3 25
-5.0%
Q2 25
-7.7%
Q1 25
-7.3%
Q4 24
-48.4%
Q3 24
-92.0%
Q2 24
-18.5%
Q1 24
-62.6%
Net Margin
DFTX
DFTX
XWIN
XWIN
Q4 25
Q3 25
-11.5%
Q2 25
-11.3%
Q1 25
-12.9%
Q4 24
Q3 24
-94.3%
Q2 24
-21.0%
Q1 24
-61.6%
EPS (diluted)
DFTX
DFTX
XWIN
XWIN
Q4 25
$-0.06
Q3 25
$-0.06
Q2 25
$-0.02
Q1 25
$-0.03
Q4 24
$0.11
Q3 24
$-0.72
Q2 24
$-0.22
Q1 24
$-0.65

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DFTX
DFTX
XWIN
XWIN
Cash + ST InvestmentsLiquidity on hand
$99.7M
$6.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$78.1M
$28.0M
Total Assets
$124.5M
$35.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DFTX
DFTX
XWIN
XWIN
Q4 25
$6.7M
Q3 25
$1.7M
Q2 25
$468.8K
Q1 25
$147.3K
Q4 24
$161.9K
Q3 24
$162.3K
Q2 24
$363.4K
Q1 24
$273.1K
Stockholders' Equity
DFTX
DFTX
XWIN
XWIN
Q4 25
$28.0M
Q3 25
$13.6M
Q2 25
$6.5M
Q1 25
$6.8M
Q4 24
$3.1M
Q3 24
$-895.9K
Q2 24
$48.2K
Q1 24
$-42.7K
Total Assets
DFTX
DFTX
XWIN
XWIN
Q4 25
$35.5M
Q3 25
$18.3M
Q2 25
$11.6M
Q1 25
$11.9M
Q4 24
$9.9M
Q3 24
$5.1M
Q2 24
$5.8M
Q1 24
$6.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DFTX
DFTX
XWIN
XWIN
Operating Cash FlowLast quarter
$-20.6M
$1.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DFTX
DFTX
XWIN
XWIN
Q4 25
$1.7M
Q3 25
$-1.9M
Q2 25
$92.5K
Q1 25
$-322.6K
Q4 24
$-263.4K
Q3 24
$-437.9K
Q2 24
$-468.7K
Q1 24
$-221.7K

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DFTX
DFTX

Segment breakdown not available.

XWIN
XWIN

North America$1.7M97%
Other$50.4K3%

Related Comparisons